Summary of Progyny Conference Call Company Overview - **Company**: Progyny - **Industry**: Healthcare Facilities, specifically women's health and family-building benefits - **Key Executives Present**: CEO Pete Anevski, CFO Mark Livingston, Chief Commercial Officer Katie Higgins, COO Melissa Cummings [1][2] Core Business and Services - Progyny provides comprehensive benefits related to women's health and family-building, including fertility, adoption, surrogacy, pregnancy, postpartum, and menopause [3][4] - The company emphasizes expert care and support for members, leading to significant revenue growth and profitability since its IPO in 2019 [4] Market Insights and Trends - The prevalence of infertility is reported as 1 in 5, highlighting a significant need for related benefits [5] - Employers are increasingly focused on providing benefits that meet employee needs while managing medical costs [5][6] - Progyny has demonstrated a 5% compounded increase in medical costs over three years, compared to 27% for the broader market, indicating effective cost management [6][7] Client Retention and Growth - Progyny added 900,000 lives in the 2025 selling season with nearly 100% client retention [8][12] - Clients are not only retaining benefits but also expanding them, with 30% of the book of business adding to their benefits [12] Diversification and Risk Management - The company has reduced its exposure to the tech industry, with the largest industry now representing only 15% of lives covered, down from 18% [17][18] - The largest client is projected to represent only a mid-single-digit percentage of revenue in 2026, mitigating individual client risk [18] New Product Launch: Progyny Select - Progyny Select is designed for small employers (100+ employees) and offers a fully insured, pooled risk model for infertility benefits [19][21] - This market represents an additional 50 million covered lives, expanding Progyny's addressable market significantly [20][24] New Services and Offerings - Recent service expansions include pregnancy, postpartum, parenting, leave and benefit navigation, and menopause, aimed at enhancing member experience [25][26] - The company is focused on integrating these services to provide a cohesive experience for members [26] Global Expansion - Progyny's acquisition of Apryl in 2024 allows for a unified global offering that addresses women's health and family-building services across different countries [28][29] - The focus is on providing local customization while maintaining global consistency [30] Financial Performance and Cash Flow - Progyny has maintained a strong conversion rate of Adjusted EBITDA to cash flow, exceeding a 75% target [31] - The company plans to continue investing in business expansion, including new offerings and go-to-market resources [32] Future Outlook - The leadership expresses confidence in the growth potential of Progyny Select and the overall business strategy for 2026 and beyond [34][61] - The company aims to demonstrate its ability to grow sustainably despite macroeconomic challenges [63] Competitive Landscape - Progyny positions itself as a leader in the market, contrasting with competitors who may struggle with cash flow and business models [51][52] - The company welcomes competition, believing the market is large enough for multiple players [52] Conclusion - Progyny is well-positioned for future growth with a diversified client base, new product offerings, and a strong focus on member experience and cost management [64]

Financial Data and Key Metrics Changes - For Q1 2025, total revenue was $1.53 billion, down from $1.6 billion in Q1 2024, primarily due to market and partnership exits, partially offset by premium growth [21] - Membership at the end of Q1 2025 was 491,000, a decrease from 523,000 in Q1 2024, reflecting a cautious approach to growth and partner exits [19] - Medical margin for Q1 2025 was $128 million, down from $157 million in Q1 2024, driven by elevated utilization and costs [21][22] - Adjusted EBITDA for Q1 2025 was $21 million, compared to $29 million in Q1 2024, reflecting ongoing elevated cost trends [23] Business Line Data and Key Metrics Changes - ACO REACH membership decreased to 114,000 in Q1 2025 from 131,000 in Q1 2024, primarily due to exiting an underperforming partnership [20] - Medical costs for Q1 2025 were in line with expectations, driven by elevated utilization and flu-related costs [22] - The medical cost trend for year two plus markets was 5.5% in Q1 2025, down from 6.7% in Q1 2024 [24] Market Data and Key Metrics Changes - The Medicare Advantage market continues to expand, with CMS data showing a year-over-year growth trend of 3.9% [10] - Overall market trends in 2025 remain consistent with the prior year, with an expected full-year trend of 5.3% [9] Company Strategy and Development Direction - The company is focused on disciplined growth, reducing exposure to costs outside of its control, and enhancing clinical and operational capabilities [6][12] - Investments in technology and clinical programs are expected to drive competitive advantages and improve quality outcomes [13][14] - The company anticipates a more favorable environment in 2026, supported by improved payer bids and final rate notices from CMS [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the final rate notice from CMS for 2026, which is expected to address high cost and utilization trends [6][18] - The company is taking a cautious approach to membership growth, with expectations for retroactive membership assignments in Q2 [5][19] - Management highlighted the importance of early identification and management of chronic diseases as a key focus of their model [7][10] Other Important Information - The company ended Q1 2025 with $369 million in cash and marketable securities, expecting to use approximately $110 million of cash in 2025 [27] - The company is maintaining a disciplined approach to capital allocation to support business objectives while aiming for cash flow breakeven in 2027 [27] Q&A Session Summary Question: Impact of V-28 risk model transition on value-based care companies - Management indicated that the risk adjustment perspective for 2025 is in line with expectations, with a 2% net increase year over year, despite a 3% headwind from V-28 [33][34] Question: Contribution from previously exited areas - Management noted that unfavorable development from exited markets would not impact 2025 significantly, with minimal remaining IBNR [37][38] Question: 2026 MA final rate notice and its flow-through - Management confirmed that 40% of membership was repriced for January 2025, with expected benefits from the average 9% increase across the network [41][42] Question: Risk scores and patient movement - Management clarified that the 2% increase in risk adjustment is on a same member basis, with some movement between payers noted but not significantly affecting care models [49][52] Question: Expectations for 2026 MA bit cycle - Management expressed optimism about the 2026 environment, with a focus on quality incentives and clinical cost-saving initiatives tracking well [58][61] Question: Medical cost trends and visibility on completed claims - Management stated that medical cost trends were in line with expectations, with improved visibility from the new financial data pipeline [65][66] Question: Potential membership reduction due to Part D - Management indicated that they are making progress in reducing Part D exposure and do not anticipate a reduction in membership for 2026 [75][76] Question: Clinical programs and their impact - Management confirmed that while 2025 is an investment year for new clinical programs, benefits are expected to materialize in 2026 and beyond [104][106]